

## Special Issue

# Infection, Virulence and Drug Resistance of Fungal Pathogen

### Message from the Guest Editor

Billions of people suffer from the growing incidence of fungal infection every year, with high morbidity and mortality rate. However, the current arsenal of antifungals is exceedingly limited due to a lack of new drug targets and the emergence of drug resistance. Furthermore, the rapid spread of the recently emerged “superbug” *Candida auris* further worsens the efficacy of first-line antifungal therapy. The diagnosis and treatment of human fungal infections remain a challenge, and tackling this challenge requires better understanding of the mechanisms contributing to fungal infection, pathogenicity, and antifungal drug resistance. A number of cutting-edge technologies, provide robust and effective tools to unravel mechanisms and identify novel targets. This Special Issue seeks manuscript submissions that further our understanding of fungal infection, virulence, and drug resistance. Submissions on the characterization of new antifungals, technologies, and antifungal strategies and mechanisms that are harnessed to combat fungal infection are especially encouraged.

### Guest Editor

Prof. Dr. Changbin Chen

The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China

### Deadline for manuscript submissions

closed (15 March 2022)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/72588](https://mdpi.com/si/72588)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)